Novartis' M&A Machine

M&A is competitive, and not all subjects are willing ones. Senior executives at Novartis, Big Pharma's number two acquirer, describe their system for identifying acquisition targets, understanding their priorities and walking away if prices get out of hand.

By Melanie Senior

With nearly $14 billion worth of acquisitions since 2005, Novartis AG has been the second-most aggressive shopper among Big Pharma....

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo